Journal Article

Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications

Al-Kaabi, Saad, Farooq, Abdulaziz, Al-Suwaidi, Jassim, Mohamed-Ali, Vidya, Al-Siddiqi, Heba H., Al-Ejeh, Fares, Al-Thani, Asmaa A., Al Maslamani, Muna, Ibrahim, Shahd, Khatib, Mohamad Y., Ouararhni, Khalid, Abdesselem, Houari B., Al-Maadheed, Mohammed, Omrani, Ali S., Hssain, Ali Ait, Decock, Julie V., Bensmail, Ilham, Razok, Almurtada, Saeed, Walaa A. H., Mohammed, Sara S. I., Al-Nesf, Maryam A. Y., Butler, Alexandra E., Al Khal, Abdullatif, Samsam, Waseem, Alhussain, Hashim, Aly, Reham M. A.

2022

Overview

COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients. Prognostic markers for patients with COVID-19 are of critical importance in determining the course of SARS-CoV-2 infection and patient handling. Here the authors determine and apply a prognostic proteomic panel for risk and drug prediction in the management of SARS-CoV-2 infected patients.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
• Subject: 49/79 / 631/250/2520 / 631/250/255/2514 / 631/326/596/4130 / 692/420/254 / 82/80 / Adult / Blood Proteins - analysis / Coronaviruses / COVID-19 / COVID-19 - drug therapy / COVID-19 - mortality / COVID-19 - pathology / Cytokines - blood / Drug development / Drugs / Female / Humanities and Social Sciences / Humans / Laboratory tests / Male / Middle Aged / multidisciplinary / Pathogenesis / Patients / Plasma / Plasma proteins / Prognosis / Proteins / Proteomics / Proteomics - methods / Risk / SARS-CoV-2 - drug effects / Science / Science (multidisciplinary) / Severe acute respiratory syndrome coronavirus 2 / Severity of Illness Index / Young Adult